Home › Research › Biomarkers
Association of Polygenic Risk Score for 5 Diseases With Alzheimer Disease Progression, Biomarkers, and Amyloid Deposition
Jingjing Liang, Sadiya Hussainy, Sara Michelle Lee, Gray Wu, Natalie Bautista, Mao Ding, Heming Wang, BONNIE J. LAFLEUR et al.. Neurology, 2025-01-21
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Among 463 ADNI participants with baseline MCI (mean age 72.6 ± 7.3 years, 43.4% female), the OSA PRS, adjusted for BMI, was significantly associated with MCI-to-AD progression. The highest OSA PRS quartile had an odds ratio of 1.86 (95% CI 1.03-3.37) at 3 years and 2.02 (95% CI 1.16-3.51) at 5 years, compared with the lowest quartile. PRSs for T2D, CAD, major depression, and BMI were not associated with MCI-to-AD progression. Participants in the highest OSA PRS quartile had higher PET amyloid deposition and greater cognitive decline. In 752 participants (mean age 74.1 ± 7.3 years, 43.6% female), OSA PRS was significantly associated with baseline levels of PET amyloid, CSF amyloid-β 42, phosphorylated tau (p-tau), visinin-like protein 1, tumor necrosis factor receptor 1, and plasma neurofilament light after multiple testing adjustments. Individuals with high polygenic susceptibility to OSA exhibited an increased risk of MCI-to-AD progression and a higher amyloid deposition rate, suggesting potential modifier effects of OSA or OSA-associated genes on AD progression and pathophysiology. However, the small sample size and lack of objective OSA diagnosis limit interpretation of these genetic effects.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 752 participants. The authors caution that the small sample size and lack of objective sleep apnea diagnosis limit interpretation, so this does not establish a treatment or prevention. Reported effect size: 43.4%; 43.6%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Liang, J., Hussainy, S., Lee, S. M., Wu, G., Bautista, N., Ding, M., et al. (2025). Association of Polygenic Risk Score for 5 Diseases With Alzheimer Disease Progression, Biomarkers, and Amyloid Deposition. Neurology. https://doi.org/10.1212/wnl.0000000000210250
Vancouver
Liang J, Hussainy S, Lee SM, Wu G, Bautista N, Ding M, et al. Association of Polygenic Risk Score for 5 Diseases With Alzheimer Disease Progression, Biomarkers, and Amyloid Deposition. Neurology. 2025. doi:10.1212/wnl.0000000000210250. PMID: 39836940.
BibTeX
@article{liang2025-39836940,
author = {Liang, Jingjing and Hussainy, Sadiya and Lee, Sara Michelle and Wu, Gray and Bautista, Natalie and Ding, Mao and Wang, Heming and LAFLEUR, BONNIE J. and others},
title = {{Association of Polygenic Risk Score for 5 Diseases With Alzheimer Disease Progression, Biomarkers, and Amyloid Deposition}},
journal = {Neurology},
year = {2025},
doi = {10.1212/wnl.0000000000210250},
pmid = {39836940},
url = {https://doi.org/10.1212/wnl.0000000000210250}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Among 463 ADNI participants with baseline MCI (mean age 72.6 ± 7.3 years, 43.4% female), the OSA PRS, adjusted for BMI, was significantly associated with MCI-to-AD progression.
- The highest OSA PRS quartile had an odds ratio of 1.86 (95% CI 1.03-3.37) at 3 years and 2.02 (95% CI 1.16-3.51) at 5 years, compared with the lowest quartile.
- PRSs for T2D, CAD, major depression, and BMI were not associated with MCI-to-AD progression.
- Participants in the highest OSA PRS quartile had higher PET amyloid deposition and greater cognitive decline.
- In 752 participants (mean age 74.1 ± 7.3 years, 43.6% female), OSA PRS was significantly associated with baseline levels of PET amyloid, CSF amyloid-β 42, phosphorylated tau (p-tau), visinin-like protein 1, tumor necrosis factor receptor 1, and plasma neurofilament light after multiple testing adjustments.
Why it matters
A genetic risk score for obstructive sleep apnea was linked to higher risk of progressing from mild cognitive impairment to Alzheimer's, and to more amyloid deposition and cognitive decline, while risk scores for type 2 diabetes, coronary artery disease, major depression and BMI were not. The authors caution that the small sample size and lack of objective sleep apnea diagnosis limit interpretation, so this does not establish a treatment or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designprospective cohort
- Participants752
- Effect size43.4%; 43.6%
- Evidence strengthModerate
How this study scored 60/100
Published in a leading specialty journal, and it is a prospective cohort study, followed forward from enrollment. Scored zero for randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 58 of the 96 points we could judge it on, which is 60 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A prospective cohort study, followed forward from enrollment |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 752 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 5 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | Brigham and Women's Hospital: institution h-index 1,995 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39836940) |
| Free to read | 2 / 2 | Free to read |
| Points | 58 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 58 of the 96 points we could judge it on is 60 out of 100. |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Biomarkers from nearby years
Also in Biomarkers
137 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.